Holen Sie sich die Stockscreener-App
20.26
0.05%
0.01
Pelthos Therapeutics Inc. Aktie (PTHS) Neueste Nachrichten
Pelthos Therapeutics (PTHS) Stock Fair Value Falls After Analysts Cut Zelsuvmi Launch Estimates - Yahoo Finance
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Rating Lowered by Zacks Research - MarketBeat
Pelthos Therapeutics director Matthew Pauls sells $16,506 in shares By Investing.com - Investing.com Australia
Pelthos Therapeutics director sells $11,560 in common stock By Investing.com - Investing.com Nigeria
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells 558 Shares of Stock - MarketBeat
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock: Insider Peter Greenleaf Sells 797 Shares - MarketBeat
Pelthos Therapeutics director Peter Greenleaf sells $16,872 in stock By Investing.com - Investing.com Nigeria
Pelthos Therapeutics director sells $11,560 in common stock - Investing.com
Pelthos Therapeutics director Peter Greenleaf sells $16,872 in stock - Investing.com
Pelthos Therapeutics director Matthew Pauls sells $16,506 in shares - Investing.com
Form 4 Pelthos Therapeutics Inc For: 6 October By Investing.com - Investing.com India
Form 4 Pelthos Therapeutics Inc For: 6 October By Investing.com - Investing.com UK
Under a trading plan, Pelthos Therapeutics (PTHS) director sells 797 shares at $21.17. - Stock Titan
For estimated vesting taxes, a Pelthos Therapeutics (PTHS) director sold 786 shares at $21. - Stock Titan
Pelthos expands ZELSUVMI coverage to 127 million lives - Investing.com
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - The Manila Times
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - GlobeNewswire
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - GlobeNewswire
PTHS PE Ratio & Valuation, Is PTHS Overvalued - Intellectia AI
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com Australia
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Pelthos Therapeutics elects directors and approves new equity plan at annual meeting - Investing.com
Pelthos Shareholders Approve 2026 Equity Plan With 500,000-Share Reserve - Minichart
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com UK
Stockholders elect eight directors as Pelthos Therapeutics (PTHS) adopts its 2026 stock incentive plan. - Stock Titan
Pelthos Therapeutics Inc (PTHS-A) Stock Price and News - The Globe and Mail
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings: Deep EPS Miss Sends Shares LowerRevenue Warning Signal - careplusvn.com
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings: Deep EPS Miss Sends Shares LowerQuarterly Earnings - dars.gov.et
Pelthos Therapeutics Inc. SEC Filing (Aug 18, 2026) - Stock Titan
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewswire
Pelthos Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Pelthos Therapeutics posts Q2 2026 revenue growth, but EPS miss weighs - Investing.com
Pelthos Therapeutics Inc. 2026: Revenue $15.6M, Net income ($23.42M), EPS ($6.62) — 10-Q Summary - TradingView
Earnings To Watch: Pelthos Therapeutics Inc (PTHS) Reports Q2 2026 Result - Yahoo Finance
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 - GlobeNewswire
Pelthos Therapeutics (PTHS) Surges 9.18% to $28.66: Key Levels to WatchIsland Reversal - careplusvn.com
Pelthos Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives 9.18% Stock JumpNegative Surprise Momentum - careplusvn.com
PTHS Q1 2026 Earnings: Smaller-than-Expected Loss Drives Modest Stock GainWeak Earnings Momentum - careplusvn.com
Pelthos Therapeutics Added to Russell 3000E™ Growth - GlobeNewswire
PTHS Forecast — Price Target — Prediction for 2027 - TradingView
Pelthos Therapeutics stock rises on director share purchase - Investing.com
Why is Pelthos Therapeutics stock rallying today? - Investing.com
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - Yahoo Finance
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pelthos Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Pelthos Therapeutics Announces First Quarter 2026 Financial Results - GlobeNewswire
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain - Yahoo Finance
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):